Xalipat 100 Injection contains Oxaliplatin 100 mg, a platinum-based chemotherapeutic agent indicated primarily for the treatment of colorectal cancer. Oxaliplatin exerts its antineoplastic effect by forming platinum-DNA adducts, leading to inhibition of DNA replication and transcription, ultimately inducing apoptosis in malignant cells. Xalipat 100 Injection is administered intravenously, typically as part of combination chemotherapy regimens such as FOLFOX, which includes fluorouracil and leucovorin. The dosage and treatment schedule should be individualized based on patient condition, tumor response, and tolerability. Common adverse effects include peripheral neuropathy, myelosuppression, gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as hypersensitivity reactions. Monitoring for hematologic parameters and neurological symptoms is essential during therapy. Oxaliplatin is contraindicated in patients with known hypersensitivity to platinum compounds and should be used with caution in those with pre-existing neuropathies or renal impairment. Adequate hydration and antiemetic prophylaxis are recommended to minimize toxicity. Xalipat 100 Injection should be prepared and administered by healthcare professionals experienced in chemotherapy. Proper handling and disposal procedures must be followed to avoid occupational exposure. This medication is intended for use under strict medical supervision in oncology settings.